Akriti Jain, MD, discussed how emerging data on non-ABL1 mutations is reshaping chronic myeloid leukemia management.

Various clinical trials have evaluated the clinical value of an initial dose intensification of imatinib in CML-CP patients (an overview of the most important response rates is given in Table 1).

ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be ...

ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to ...

The prognosis and outcomes of patients with Philadelphia chromosome (Ph) chronic myeloid leukemia (CML) has been revolutionized by the development of the small-molecule targeted therapy imatinib.

(a) Peripheral blood smear in a patient with the chronic phase of chronic myeloid leukemia (CML) before treatment; (b) Detection of BCR::ABL1 fusion gene, p210 by RNA sequencing; (c) Peripheral ...

Revenue in 2024 increased 342%year-over-year to US$134.3 million (RMB980.7 million), attributable in part to Takeda’s option payment and strong ...